In a reader survey, researchers and core lab staff share how they think cores are doing.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.
Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.
The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
Researchers were able to classify 1,244 of 4,585 putatively clinically relevant rare variants genotyped on the UKB microarray as high quality.
The company reported $853 million in total revenues for the quarter, driven by growth across its sequencing and microarray products.
The collaboration will focus on the development of a bespoke silicon array to enable high-throughput production of high-fidelity gene-length DNA.
Under the terms of the deal, Beijing-based GeneCast has the exclusive right to market Agendia's MammaPrint and BluePrint tests to Chinese customers.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
A new analysis finds some cancers receive more nonprofit dollars than others.
An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.
In Science this week: comparative analysis of sex differences in mammal gene expression, and more.